The experts present and discuss a case of a patient with KIT exon 9-mutated GIST, an including an overview of surgical options.
Targeted Oncology
Articles by Targeted Oncology
The panelists discuss the phase 3 INVICTUS trial of ripretinib and the phase 1 study of ripretinib intra-patient dose escalation.
Third-line treatment recommendations for patients with GIST and a discussion on side effect management.
Experts discuss the considerations of lines of therapy, comment on molecular testing, and the role of repeat biopsies.
The experts discuss a case presentation of a 66-year-old woman with heavily pretreated GIST, and comment on follow-up times and treatment options.
Experts review 3 clinical cases, discuss treatment options and relevant clinical trials in GIST.
Ruth He, MD, grants advice on how to treat patients with unresectable hepatocellular carcinoma.
Ruth He, MD, discusses potential options for physicians in their treatment of unresectable hepatocellular carcinoma.
Ruth He, MD, acknowledges the current struggles experts face in combatting unresectable hepatocellular carcinoma.
Ruth He, MD, discusses the approval of frontline atezolizumab-bevacizumab and its relation to subsequent treatment of patients with unresectable hepatocellular carcinoma.
Atezolizumab and Bevacizumab in the Phase 3 IMbrave150 Trial
Published: | Updated:
Ruth He, MD, discusses major takeaways from the phase 3 IMbrave150 trial of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma.
Ruth He, MD, highlights factors that influence her use of frontline systemic therapy in patients with unresectable hepatocellular carcinoma.
Ruth He, MD, discusses the current treatment options for unresectable hepatocellular carcinoma.
Final analysis of data on HER2-positive disease presented at the 2020 San Antonio Breast Cancer Symposium from experts in the field of breast oncology.
Experts in breast oncology discuss the evolving role of trastuzumab deruxtecan for metastatic HER2-positive breast cancer.
Hatem Soliman, MD, reviews statistically significant data from the PERTAIN study, presented at the 2020 San Antonio Breast Cancer Symposium.
Experts in breast oncology discuss their real-world experience with trastuzumab emtansine (T-DM1) for patients with advanced HER2-positive breast cancer.
Analysis from the ALTTO (BIG 2-06) trial and the relationship between a short or long disease-free interval and overall survival.
Updated findings on the use of neratinib for HER2+ breast cancer from the 2020 SABCS Virtual Symposium.
Updated findings on the use of neratinib for HER2+ breast cancer from the 2020 SABCS Virtual Symposium.
A discussion on the importance of prognostic tools for early stage breast cancer.
Hatem Soliman, MD, discusses data presented at the 2020 SABCS for patients with HER2-enriched subtypes that showed benefit from CDK4/6 inhibition.
Andrew Seidman, MD, provides insight on clinical sequencing for patients with advanced HER2-positive breast cancer.
Experts in breast oncology discuss the evolving landscape in early stage and metastatic HER2-positive breast cancer.
Steven Sherman, MD, FACE, provides closing thoughts on unmet needs and future directions for the treatment of patients with RAI-refractory DTC.
Approaching patient education of RAI-refractory DTC therapy with lenvatinib, fostering open communication between patients and providers, and monitoring medication adherence.
An expert endocrinologist perspective on managing the toxicities associated with lenvatinib when treating RAI-refractory DTC and the role of dose reduction and interruption.
A review of a multicenter phase 2 study evaluating the safety and efficacy of lenvatinib starting doses in RAI-refractory DTC.
A review of the phase 3 SELECT trial examining the use of lenvatinib for the treatment of RAI-refractory DTC and the management of adverse events.
Steven Sherman, MD, FACE, provides an overview of the history and evolution of treating patients with RAI [radioactive iodine]–refractory differentiated thyroid cancer [DTC].